Sugi Predict

Sugi Predict / Compounds / SCHEMBL669632

SCHEMBL669632

SCHEMBL669632

CCOC(=O)c1cccc(SCc2ccc(OC)cc2)c1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.46
▸ MAPT P10636 4/20 0.46
▸ LMNA P02545 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ HPGD P15428 6/20 0.45
▸ ALDH1A1 P00352 6/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.44
▸ HTT P42858 3/20 0.44
▸ TP53 P04637 2/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ KDM4E B2RXH2 3/20 0.43
▸ TSHR P16473 3/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.42
▸ TDP1 Q9NUW8 2/20 0.42
▸ CCR6 P51684 1/20 0.42
▸ HKDC1 Q2TB90 1/20 0.42
▸ DDX3X O00571 1/20 0.42
▸ NPC1 O15118 3/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ CACNA1B Q00975 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL670079 0.82 MAPT (0.41) KMT2AMAPTLMNAMEN1HPGD
SCHEMBL19389518 0.78 APP (0.45) KMT2ALMNAMEN1ALDH1A1SMN1; SMN2
SCHEMBL669910 0.77 TSHR (0.50) KMT2AMAPTLMNAMEN1HPGD
SCHEMBL11876582 0.76 BRD4 (0.46) KMT2AMAPTLMNAMEN1HPGD
SCHEMBL28326285 0.76 POLB (0.58) KMT2AMAPTLMNAMEN1HPGD
SCHEMBL23131330 0.74 TSHR (0.46) KMT2AMAPTLMNAMEN1HPGD
SCHEMBL30786194 0.74 MEN1 (0.44) KMT2AMAPTLMNAMEN1HPGD
SCHEMBL17080275 0.74 MEN1 (0.44) KMT2AMAPTLMNAMEN1HPGD
Ammonia Solution, Strong SCHEMBL11193904 0.74 KMT2A (0.59) KMT2AMAPTLMNAMEN1ALDH1A1
SCHEMBL6290570 0.74 RAB9A (0.67) KMT2AMAPTLMNAMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12458627-B2 Autotaxin inhibitors and uses thereof DF 2024 IP ACQUISITION, LLC (US) 2025-11-04 — — US disclosed
US-12268668-B2 Autotaxin inhibitor compounds SABRE THERAPEUTICS LLC (US) 2025-04-08 — — US disclosed
US-20240189281-A1 AUTOTAXIN INHIBITOR COMPOUNDS SABRE THERAPEUTICS LLC (US) 2024-06-13 — — US disclosed
US-11779568-B2 Autotaxin inhibitor compounds SABRE THERAPEUTICS LLC (US) 2023-10-10 — — US disclosed
US-11779568-B2 Autotaxin inhibitor compounds SABRE THERAPEUTICS LLC (US) 2023-10-10 — — US disclosed
CN-116059203-A Autotaxin inhibitors and uses thereof 赛博治疗有限责任公司 2023-05-05 — — CN disclosed
CN-110372671-B Autotaxin inhibitor compounds 赛博治疗有限责任公司 2023-02-21 — — CN disclosed
US-20220265608-A1 AUTOTAXIN INHIBITOR COMPOUNDS DF 2024 IP ACQUISITION, LLC 2022-08-25 — — US disclosed
EP-4026549-A1 AUTOTAXIN INHIBITORS AND USES THEREOF Sabre Therapeutics LLC (US) 2022-07-13 — — EP disclosed
EP-4026549-A1 AUTOTAXIN INHIBITORS AND USES THEREOF Sabre Therapeutics LLC (US) 2022-07-13 — — EP disclosed
US-9000025-B2 Autotaxin inhibitors and uses thereof AMIRA PHARMACEUTICALS, INC. (US) 2015-04-07 — — US disclosed
US-9000025-B2 Autotaxin inhibitors and uses thereof AMIRA PHARMACEUTICALS, INC. (US) 2015-04-07 — — US disclosed
WO-2015048301-A1 AUTOTAXIN INHIBITOR COMPOUNDS PHARMAKEA, INC. (US) 2015-04-02 — — WO disclosed
WO-2015048301-A1 AUTOTAXIN INHIBITOR COMPOUNDS PHARMAKEA, INC. (US) 2015-04-02 — — WO disclosed
EP-2606031-A2 AUTOTAXIN INHIBITORS AND USES THEREOF Amira Pharmaceuticals, Inc. (US) 2013-06-26 — — EP disclosed
US-20130150326-A1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2013-06-13 — — US disclosed
US-20130150326-A1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2013-06-13 — — US disclosed
US-20130150326-A1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2013-06-13 — — US disclosed
WO-2012024620-A2 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2012-02-23 — — WO disclosed
WO-2012024620-A2 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2012-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150326-A1 AUTOTAXIN INHIBITORS AND USES THEREOF ENPP2, SERPINB1, SERPINE1 KMT2A 3249/4885MAPT 447/4885LMNA 1423/4885
US-11779568-B2 Autotaxin inhibitor compounds ENPP2, SERPINB1, SERPINE1 KMT2A 2780/4885MAPT 293/4885LMNA 1232/4885
US-12458627-B2 Autotaxin inhibitors and uses thereof ENPP2, SERPINB1, RNASE1 KMT2A 2862/4885MAPT 580/4885LMNA 1189/4885
US-20240189281-A1 AUTOTAXIN INHIBITOR COMPOUNDS ENPP2, SERPINB1, SERPINE1 KMT2A 2780/4885MAPT 293/4885LMNA 1232/4885
US-20220265608-A1 AUTOTAXIN INHIBITOR COMPOUNDS ENPP2, SERPINB1, SERPINE1 KMT2A 2780/4885MAPT 293/4885LMNA 1232/4885
US-12268668-B2 Autotaxin inhibitor compounds ENPP2, SERPINB1, SERPINE1 KMT2A 2780/4885MAPT 293/4885LMNA 1232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.